Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged … Read more
Anixa Biosciences Inc - Asset Resilience Ratio
Anixa Biosciences Inc (ANIX) has an Asset Resilience Ratio of 83.08% as of January 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Anixa Biosciences Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Anixa Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $12.65 Million | 83.08% |
| Total Liquid Assets | $12.65 Million | 83.08% |
Asset Resilience Insights
- Very High Liquidity: Anixa Biosciences Inc maintains exceptional liquid asset reserves at 83.08% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Anixa Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Anixa Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Anixa Biosciences Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Anixa Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-10-31 | 86.63% | $13.93 Million | $16.08 Million | +0.24pp |
| 2024-10-31 | 86.39% | $18.65 Million | $21.59 Million | -3.45pp |
| 2023-10-31 | 89.84% | $22.93 Million | $25.52 Million | +32.87pp |
| 2022-10-31 | 56.97% | $17.33 Million | $30.41 Million | +38.77pp |
| 2021-10-31 | 18.20% | $6.60 Million | $36.26 Million | -9.73pp |
| 2020-10-31 | 27.93% | $2.64 Million | $9.45 Million | -9.41pp |
| 2019-10-31 | 37.34% | $2.35 Million | $6.29 Million | +6.32pp |
| 2018-10-31 | 31.01% | $2.00 Million | $6.45 Million | -8.70pp |
| 2017-10-31 | 39.72% | $3.50 Million | $8.81 Million | +26.39pp |
| 2016-10-31 | 13.33% | $750.00K | $5.63 Million | -12.38pp |
| 2015-10-31 | 25.71% | $2.40 Million | $9.34 Million | -1.90pp |
| 2014-10-31 | 27.61% | $2.50 Million | $9.06 Million | +18.78pp |
| 2012-10-31 | 8.83% | $500.00K | $5.66 Million | -17.18pp |
| 2011-10-31 | 26.01% | $2.25 Million | $8.65 Million | +18.40pp |
| 2009-10-31 | 7.61% | $749.94K | $9.85 Million | -11.62pp |
| 2008-10-31 | 19.24% | $1.44 Million | $7.50 Million | -2.15pp |
| 2007-10-31 | 21.39% | $400.00K | $1.87 Million | +19.35pp |
| 2006-10-31 | 2.04% | $38.00K | $1.86 Million | -25.31pp |
| 2005-10-31 | 27.35% | $401.00K | $1.47 Million | +25.94pp |
| 2000-10-31 | 1.41% | $96.87K | $6.89 Million | -4.77pp |
| 1999-10-31 | 6.17% | $500.00K | $8.10 Million | -- |